Nxera Pharma Co Ltd 4565
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Trading Information
- Previous Close Price
- ¥1,308.00
- Day Range
- ¥1,288.00–1,320.00
- 52-Week Range
- ¥1,237.00–1,826.00
- Bid/Ask
- ¥1,291.00 / ¥1,297.00
- Market Cap
- ¥116.60 Bil
- Volume/Avg
- 561,200 / 1.0 Mil
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 4.84
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Nxera Pharma Co Ltd is a science and technology-led biopharmaceutical company. Its activities are drug discovery, drug development and the commercialization of pharmaceutical products. The focus is to discover new medicines for unmet medical needs, including novel small molecules, peptides and therapeutic antibodies targeting G Protein-Coupled Receptors (“GPCRs”).
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Growth
- Total Number of Employees
- 360
- Website
- https://www.nxera.life
Comparables
Valuation
|
Metric
|
4565
|
190A
|
IMU
|
|---|---|---|---|
Price/Earnings (Normalized) | — | — | — |
Price/Book Value | 1.70 | — | 3.10 |
Price/Sales | 4.84 | — | — |
Price/Cash Flow | — | — | — |
Price/Earnings
4565
190A
IMU
Financial Strength
|
Metric
|
4565
|
190A
|
IMU
|
|---|---|---|---|
Quick Ratio | 3.85 | 23.49 | 3.66 |
Current Ratio | 4.11 | 24.76 | 3.86 |
Interest Coverage | −3.39 | — | −321.34 |
Quick Ratio
4565
190A
IMU
Profitability
|
Metric
|
4565
|
190A
|
IMU
|
|---|---|---|---|
Return on Assets (Normalized) | −5.96% | −52.00% | −67.09% |
Return on Equity (Normalized) | −13.30% | −55.58% | −77.26% |
Return on Invested Capital (Normalized) | −5.85% | −55.58% | −79.58% |
Return on Assets
4565
190A
IMU
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Novo Nordisk AS ADR
NVO
| Nxfmkpktd | Hzvc | $554.5 Bil | |||
| Vertex Pharmaceuticals Inc
VRTX
| Dknnqfys | Mbshzz | $119.5 Bil | |||
| Regeneron Pharmaceuticals Inc
REGN
| Xbvctkf | Dpvyn | $114.6 Bil | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Xzsjpscx | Hdkbm | $35.2 Bil | |||
| argenx SE ADR
ARGX
| Zczbznvf | Xkbb | $31.7 Bil | |||
| BioNTech SE ADR
BNTX
| Kczzfspzg | Qxrv | $28.0 Bil | |||
| Moderna Inc
MRNA
| Vhyfgdwn | Yxxdn | $24.6 Bil | |||
| United Therapeutics Corp
UTHR
| Rhpwcxwbt | Nbz | $15.9 Bil | |||
| Biomarin Pharmaceutical Inc
BMRN
| Qmyycbz | Rzyznl | $13.4 Bil | |||
| Royalty Pharma PLC Class A
RPRX
| Bjfqnvmng | Crfrdw | $12.6 Bil |
United States